Display options
Cite
Heitkötter B, Steinestel K, Trautmann M, et al. Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget. 2018;9(11):9867-9874doi: 10.18632/oncotarget.23984.
Heitkötter, B., Steinestel, K., Trautmann, M., Grünewald, I., Barth, P., Gevensleben, H., Bögemann, M., Wardelmann, E., Hartmann, W., Rahbar, K., & Huss, S. (2018). Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget, 9(11), 9867-9874. https://doi.org/10.18632/oncotarget.23984
Heitkötter, Birthe, et al. "Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid." Oncotarget vol. 9,11 (2018): 9867-9874. doi: https://doi.org/10.18632/oncotarget.23984
Heitkötter B, Steinestel K, Trautmann M, Grünewald I, Barth P, Gevensleben H, Bögemann M, Wardelmann E, Hartmann W, Rahbar K, Huss S. Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget. 2018 Jan 04;9(11):9867-9874. doi: 10.18632/oncotarget.23984. eCollection 2018 Feb 09. PMID: 29515776; PMCID: PMC5839407.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Jan 04;9(11):9867-9874. doi: 10.18632/oncotarget.23984. eCollection 2018 Feb 09.

Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid.

Oncotarget

Birthe Heitkötter, Konrad Steinestel, Marcel Trautmann, Inga Grünewald, Peter Barth, Heidrun Gevensleben, Martin Bögemann, Eva Wardelmann, Wolfgang Hartmann, Kambiz Rahbar, Sebastian Huss

Affiliations

  1. Gerhard Domagk Institute of Pathology, University of Münster, Münster, Germany.
  2. Institute of Pathology, Military Hospital Ulm, Ulm, Germany.
  3. Institute of Pathology, Neuss, Germany.
  4. Department of Urology, University Hospital Münster, University of Münster, Münster, Germany.
  5. Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.

PMID: 29515776 PMCID: PMC5839407 DOI: 10.18632/oncotarget.23984

Abstract

AIM: PSMA (prostate-specific membrane antigen) is physiologically expressed in normal prostate tissue and over expressed in prostate cancer cells, therefore constituting a potential target for antibody-based radioligand therapy. Very recent imaging findings reported PSMA-PET/CT uptake in various thyroid lesions. We were therefore encouraged to systematically analyse PSMA expression in different benign and malignant thyroid lesions.

METHODS: Immunohistochemistry was used to detect PSMA expression in 101 thyroid lesions, while neovasculature was identified by CD34 immunostaining.

RESULTS: PSMA expression in the neovasculature was significantly more frequent in malignant tumors (36/63; 57.1%) compared to benign diseases (5/38; 13.2%;

CONCLUSIONS: We conclude that neovascular PSMA expression is common in thyroid cancer but may also rarely be found in benign thyroid diseases, such as follicular adenoma. High expression in the tumor-associated neovasculature is predominantly found in poorly differentiated and undifferentiated (anaplastic) thyroid cancer. This knowledge is highly relevant when interpreting PSMA/PET-CT scans from patients with prostate cancer. In addition, our findings might provide a rationale for further evaluation of PSMA-targeted anti-neovascular or radioligand therapy in metastatic dedifferentiated thyroid cancer.

Keywords: PSMA; prostate cancer; thyroid cancer; tumor neoangiogenesis

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that there is no conflicts of interests associated with this manuscript.

References

  1. Clin Nucl Med. 2016 Apr;41(4):331-2 - PubMed
  2. Clin Nucl Med. 2017 Jan;42(1):20-25 - PubMed
  3. J Nucl Med Technol. 2016 Sep;44(3):199-200 - PubMed
  4. Clin Cancer Res. 2016 Jul 1;22(13):3157-63 - PubMed
  5. EJNMMI Res. 2015 Dec;5(1):114 - PubMed
  6. Mol Cell Biol. 2006 Jul;26(14):5310-24 - PubMed
  7. Curr Med Chem. 2012;19(9):1346-59 - PubMed
  8. J Urol. 2003 Nov;170(5):1717-21 - PubMed
  9. Clin Cancer Res. 1997 Jan;3(1):81-5 - PubMed
  10. Clin Nucl Med. 2016 May;41(5):e263-5 - PubMed
  11. Cancer Res. 1999 Jul 1;59(13):3192-8 - PubMed
  12. Blood. 1990 Jun 15;75(12):2417-26 - PubMed
  13. Clin Cancer Res. 1996 Sep;2(9):1445-51 - PubMed
  14. Oncotarget. 2016 Mar 15;7(11):12477-88 - PubMed
  15. Oncotarget. 2017 Jan 17;8(3):4268-4276 - PubMed
  16. J Nucl Med. 2016 Aug;57(8):1170-6 - PubMed
  17. Angiogenesis. 2012 Mar;15(1):151-63 - PubMed
  18. Eur Urol. 2016 Jul;70(1):161-175 - PubMed
  19. J Carcinog. 2006 Aug 15;5:21 - PubMed
  20. Cancer. 1998 Jun 1;82(11):2256-61 - PubMed
  21. Urol Oncol. 2009 Sep-Oct;27(5):525-8 - PubMed
  22. PLoS One. 2015 May 15;10(5):e0125924 - PubMed
  23. J Nucl Med. 2016 Apr;57(4):563-7 - PubMed
  24. Clin Cancer Res. 1999 Oct;5(10):2674-81 - PubMed
  25. Sci Rep. 2017 Jul 12;7(1):5202 - PubMed
  26. Arch Pathol Lab Med. 2011 Nov;135(11):1486-9 - PubMed
  27. Int J Cancer. 1995 Sep 4;62(5):552-8 - PubMed
  28. Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):749-53 - PubMed
  29. Med Oncol. 2012 Sep;29(3):2234-9 - PubMed
  30. J Cell Biochem. 2004 Feb 15;91(3):528-39 - PubMed
  31. Hum Pathol. 2011 Nov;42(11):1667-75 - PubMed
  32. J Clin Oncol. 2007 Feb 10;25(5):540-7 - PubMed
  33. Lab Invest. 1990 Jun;62(6):690-6 - PubMed

Publication Types